(-)-Physostigmine

275.35

275.35

200-332-8

9U1VM840SP

30782

2811|2757

DTXSID3023471

ORTHORHOMBIC SPHENOIDAL PRISMS OR CLUSTERS OF LEAFLETS FROM ETHER OR BENZENE|WHITE MICROCRYSTALLINE POWDER|Colorless or pinkish crystals

S - Sensory organs|V - Various

44.8

1.7

Off-white Powder

1.2±0.1 g/cm3

105.5 °C

422.3±55.0 °C at 760 mmHg

>100℃

1.616

soluble in water (1:75), alcohol (1:10), chloroform (1:1), ether (1:30), and DMSO.

2-8°C

Oral-Rat  LD50 4.5  mg/kg; Oral-Mouse LD50: 3 mg/kg

Combustible; Fire site decomposes toxic nitrogen oxide gas

D17 -76° (c = 1.3 in chloroform); D25 -120° (benzene)

ODORLESS

6.12None

6.12|K1= 7.6X10-7; K2= 5.7X10-13

HYGROSCOPIC|White, shiny crystals or white powder; solubilities of approximately 13.3 mg/ml in water and 62.5 mg/ml in alcohol at 25 °C. /Physostigmine salicylate/|White, odorless, microcrystalline powder which is deliquescent in moist air and has solubilities of approximately 0.25 g/ml in water and 2.5 g/ml in alcohol at 25 °C. /Physostigmine sulfate/|Commercially available ophthalmic solutions of physostigmine have a pH of 2-4.

No rapid reaction with air. No rapid reaction with water.

Amines, Phosphines, and Pyridines

II

6.1(a)

UN 1544 6.1/PG 1

3

26/28

23-45-25

TJ2100000

T+

The warehouse is low-temperature, ventilated and dry; stored separately from food materials

Physostigmine solutions are sensitive to heat and light and should not be used if they become cloudy or dark brown. /Physostigmine salicylate ophthalmic solution USP/

P260-P284-P301 + P310 + P330-P304 + P340 + P310-P403 + P233

H300 + H330

Benzalkonium chloride is incompatible with physostigmine salicylate but is compatible with physostigmine sulfate.

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

It is a slight fire hazard. When heated to decomposition it emits toxic fumes of nitrogen oxides. Keep from light and heat. (EPA, 1998)

|Danger|H300: Fatal if swallowed [Danger Acute toxicity, oral]|P260, P264, P270, P271, P284, P301+P310, P304+P340, P310, P320, P321, P330, P403+P233, P405, and P501|H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]|Aggregated GHS information provided by 42 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|P260, P264, P270, P301+P310, P309+P311, P314, P321, P330, P405, and P501

This is a carbamate pesticide. As for carbamate pesticides, wear self-contained breathing apparatus when fighting fires. Extinguish fire using agent suitable for type of surrounding fire (material itself burns with difficulty). Use water in flooding quantities as fog. Use alcohol foam, carbon dioxide or dry chemical. (EPA, 1998)

Excerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]: As an immediate precautionary measure, isolate spill or leak area in all directions for at least 50 meters (150 feet) for liquids and at least 25 meters (75 feet) for solids. SPILL: Increase, in the downwind direction, as necessary, the isolation distance shown above. FIRE: If tank, rail car or tank truck is involved in a fire, ISOLATE for 800 meters (1/2 mile) in all directions; also, consider initial evacuation for 800 meters (1/2 mile) in all directions. (ERG, 2016)

This is a carbamate pesticide. As for other carbamate pesticides, avoid breathing dusts, and fumes from burning materials. Keep upwind. Avoid bodily contact with the material. Wash away any material which may have contacted the body with copious amounts of water or soap and water. (EPA, 1998)

For emergency situations, wear a positive pressure, pressure-demand, full facepiece self-contained breathing apparatus (SCBA) or pressure- demand supplied air respirator with escape SCBA and a fully-encapsulating, chemical resistant suit. (EPA, 1998)

Fire Hazard: Slight

Releases of CERCLA hazardous substances are subject to the release reporting requirement of CERCLA section 103, codified at 40 CFR part 302, in addition to the requirements of 40 CFR part 355. Physostigmine is an extremely hazardous substance (EHS) subject to reporting requirements when stored in amounts in excess of its threshold planning quantity (TPQ) of 100/10,000 lbs.

most toxic

Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain.

ACTIONS OF ANTICHOLINESTERASE AGENTS ON AUTONOMIC EFFECTOR CELLS & ON CORTICAL & SUBCORTICAL SITES IN CNS, WHERE RECEPTORS ARE LARGELY OF MUSCARINIC TYPE, ARE BLOCKED BY ATROPINE. /ANTI-CHOLINESTERASE AGENTS/|VARIOUS ACTIONS OF ANTI-CHOLINESTERASE AGENTS ON SKELETAL MUSCLE ARE AUGMENTED BY EPINEPHRINE OR EPHEDRINE ... & BLOCKED BY D-TUBOCURARINE. /ANTICHOLINESTERASEAGENTS/|SUFFICIENT CONCN OF ... PHYSOSTIGMINE ... PREVENTS ALKYLPHOSPHORYLATION OF ACETYLCHOLINESTERASE BY DIISOPROPYLFLUORO PHOSPHATE OCCUPATION OF ACTIVE SITES OF /CHOLINESTERASE/ ENZYME BY THE SHORTER ACTING DRUG PREVENTS ... ALKYLPHOSPHORYLATION BY ORGANOPHOSPHORUS CMPD ... IN VITRO & IN VIVO.|TOXOGONIN GIVEN 15 MIN PRIOR TO ADMIN OF PHYSOSTIGMINE CAUSED REDN IN TOXICITY TO MICE OF PHYSOSTIGMINE. PRALIDOXIME MESYLATE ALSO CAUSED SLIGHT REDN.|For more Interactions (Complete) data for PHYSOSTIGMINE (9 total), please visit the HSDB record page.

Physostigmine, an indirect-acting parasympathomimetic agent, is an alkaloid usually obtained from the dried ripe seeds of Physostigma venenosum.|FROM CALABAR BEANS, THE SEEDS OF THE VINE PHYSOSTIGMA VENENOSUM BALF, LEGUMINOSAE.

For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.|Prevention of organophosphate poisoning

Antidotes; Cholinesterase Inhibitors; Miotics; Parasympathomimetics|ANTICHOLINESTERASE AGENTS ARE OF GREAT VALUE IN MANAGEMENT OF PRIMARY /GLAUCOMA/AS WELL AS OF CERTAIN CATEGORIES OF SECONDARY /GLAUCOMA/ ... (EG APHAGIC GLAUCOMA, FOLLOWING CATARACT EXTRACTION); THE CONGENITAL TYPE RARELY RESPONDS TO OTHER THAN SURGICAL TREATMENT. PRIMARY GLAUCOMA IS SUBDIVIDED INTO NARROW-ANGLE (ACUTE CONGESTIVE) AND WIDE-ANGLE (CHRONIC SIMPLE) TYPES ... ANTICHOLINESTERASE AGENTS PRODUCE A FALL IN INTRAOCULAR PRESSURE IN BOTH TYPES ... BY LOWERING THE RESISTANCE TO OUTFLOW OF THE AQAEOUS HUMOR. ... /IN/ ACUTE CONGESTIVE GLAUCOMA ... MIOSIS IS ACHIEVED BY THE APPLICATION OF PILOCARPINE. ONE OR TWO DROPS OF 2% OR 4% PILOCARPINE NITRATE IS ADMINSTERED AT 10 TO 15 MIN INTERVALS FOR 1 HR; THEREAFTER, THE DRUG IS GIVEN EVERY 2 TO 3 HR. SOME OPHTHALMOLOGISTS ADMINISTER PHYSOSTIGMINE SALICYLATE IN ADDITION TO PILOCARPINE. ... CHRONIC WIDE-ANGLE & SECONDARY GLAUCOMA REQUIRE CAREFUL CONSIDERATION OF THE NEEDS OF THE INDIVIDUAL PATIENT IN SELECTING DRUG OR COMBINATION OF DRUGS ... CHOICES AVAIL INCLUDE ... ANTICHOLISNESTERASE AGENTS THAT ARE SHORT ACTING (EG PHYSOSTIGMINE SALICYLATE, 0.25% AND 0.5%) ... . /PHYSOSTIGMINE SALICYLATE/|IN CONTRAST /TO TREATMENT OF GLAUCOMA WITH POTENT, LONG ACTING ANTI-CHOLINESTERASE AGENTS/, TREATMENT WITH PILOCARPINE (4%), ALONE OR IN COMBINATION WITH PHYSOSTIGMINE (0.2%), 1-5 TIMES DAILY, WAS FOUND TO ENTAIL NO HIGHER INCIDENCE OF DEVELOPMENT OF LENTICULAR OPACITIES THAN APPEARED SPONTANEOUSLY IN UNTREATED PATIENTS IN COMPARABLE AGE GROUP.|MANY OF THE PERIPHERAL & CENTRAL EFFECTS OF ... ATROPINE & RELATED ANTIMUSCARINIC DRUGS CAN BE REVERSED BY IV ... PHYSOSTIGMINE. THE EFFECTIVENESS OF PHYSOSTIGMINE SALICYLATE MAY BE USEFUL IN REVERSING THE CENTRAL ANTICHOLINERGIC SYNDROME PRODUCED BY OVERDOSAGE OR AN UNUSUAL REACTION TO THESE DRUGS. INITIAL IV OR IM DOSE OF 2 MG IS INDICATED WITH ADDITIONAL INCREMENTS GIVEN AS NECESSARY.|For more Therapeutic Uses (Complete) data for PHYSOSTIGMINE (20 total), please visit the HSDB record page.

PHYSOSTIGMINE OFTEN CAUSES HYPEREMIA OF CONJUNCTIVA. ... RARELY TOLERATED FOR PROLONGED PERIODS BECAUSE CONJUNCTIVITIS & ALLERGIC REACTIONS OCCUR FREQUENTLY. LONG TERM ADMIN CAN PRODUCE FOLLICLES IN THE CONJUNCTIVA. IN PROLONGED TREATMENT WITH PHYSOSTIGMINE OINTMENT MAY CAUSE PIGMENTATION OF LID MARGINS.|THE CONJUNCTIVAL INSTILLATION OF SOLN ... MAY RESULT IN SYSTEMIC EFFECTS IF MEASURES (EG PRESSURE ON INNER CANTHUS) ARE NOT TAKEN TO PREVENT ABSORPTION FROM NASAL MUCOSA.|... CONTRAINDICATED IN ASTHMATIC PATIENT. IT SHOULD NOT BE EMPLOYED ALONG WITH CHOLINE ESTERS EXCEPT FOR OPHTHALMOLOGIC USE. /NEOSTIGMINE/|VET: ITS CATHARTIC ACTION IN CATTLE IS OFTEN PAINFUL. ... CONTRAINDICATED IN ... IMMOVABLE INTESTINAL OBSTRUCTION, CARDIAC OR PULMONARY DISEASES, & IN AGED ... ANIMALS.|For more Drug Warnings (Complete) data for PHYSOSTIGMINE (12 total), please visit the HSDB record page.

Tolerance to physostigmine may develop with prolonged use. Effectiveness may be restored by changing to another miotic for a short time and then resuming the original medication.

Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia.

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)|Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. (See all compounds classified as Miotics.)

PHYSOSTIGMINE IS READILY ABSORBED FROM GI TRACT, SC TISSUES, & MUCOUS MEMBRANES. ... RENAL EXCRETION PLAYS ONLY MINOR ROLE IN ITS DISPOSAL.|PHYSOSTIGMINE, A TERTIARY AMINE, CROSSES THE BLOOD-BRAIN BARRIER IN CONTRAST TO THE QUATERNARY ANTI-ACETYL CHOLINESTERASE DRUGS. /ACETYLCHOLINESTERASE/|Easily penetrates the blood-brain barrier.|Time to peak effect: iv within 5 min; duration of action: iv approximately 1 to 2 hr.|Very small amounts eliminated in urine; largely destroyed in body by hydrolysis.

Quickly hydrolyzed by cholinesterases|/PHYSOSTIGMINE/ IS LARGELY DESTROYED IN BODY, MAINLY BY HYDROLYTIC CLEAVAGE @ ESTER LINKAGE BY PLASMA ESTERASES. ... IN MAN, 1 MG DOSE ... INJECTED SC IS LARGELY DESTROYED IN 2 HR.|/PHYSOSTIGMINE/ COMBINES WITH THE ENZYME AT THE ESTERATIC SITE TO YIELD THE INACTIVE METHYLCARBAMOYL ENZYME.|Rapidly hydrolyzed by cholinesterases.

Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse.|CHARACTERISTIC PHARMACOLOGICAL EFFECTS OF ANTICHOLINESTERASE AGENTS ARE DUE PRIMARILY TO PREVENTION OF HYDROLYSIS OF ACETYLCHOLINE BY ACETYLCHOLINESTERASE @ SITES OF CHOLINERGIC TRANSMISSION. TRANSMITTER THUS ACCUMULATES, AND THE ACTION OF ACETYLCHOLINE THAT IS LIBERATED BY CHOLINERGIC IMPULSES OR THAT LEAKS FROM THE NERVE ENDING IS ENHANCED. /ACETYLCHOLINE/|... PHYSOSTIGMINE, A TERTIARY AMINE, EXERTS /MINIMAL/ EFFECTS NOT RELATED TO ACETYLCHOLINESTERASE INHIBITION. AT SUFFICIENTLY HIGH DOSAGE, HOWEVER, IT HAS DIRECT BLOCKING ACTION AT AUTONOMIC GANGLIA.|In chronic open-angle glaucoma, the exact mechanism by which miotics lower intraocular pressure is not precisely known; however, contraction of the ciliary muscle apparently opens the intratubular spaces and facilitates aqueous humor outflow.|Antagonizes action of anticholinergics, which block the post-synaptic receptor sites of acetylcholine, by inhibiting the destruction of acetylcholine by acetylcholinesterase, thereby increasing the concentration of acetylcholine at sites of cholinergic transmission.

Super toxic. Probable oral lethal dose is less than 5 mg/kg for a 70 kg (150 lb.) person. Material is a cholinesterase inhibitor. Effects of exposure may involve the respiratory, gastrointestinal, cardiovascular and central nervous systems. Death occurs due to respiratory paralysis or impaired cardiac function. Time to death may vary from 5 minutes to 24 hours, in severely poisoned patients, depending on factors such as the dose and route. Persons with asthma and/or persons that require drugs containing choline esters are at risk. (EPA, 1998)

Note: Physostigmine is a cholinesterase inhibitor. Signs and Symptoms of Physostigmine Exposure: Acute exposure to physostigmine usually leads to a cholinergic crisis. Signs and symptoms may include increased salivation, profuse sweating, lacrimation (tearing), spontaneous defecation, and spontaneous urination. Pinpoint pupils, blurred vision, headache, tremors, muscle twitching, slight paralysis, and loss of muscle coordination may occur. Malaise, mental confusion, convulsions, loss of consciousness, and coma may also be noted. Gastrointestinal effects include nausea, vomiting, diarrhea, and abdominal pain. Bradycardia (slow heart rate) occurs frequently. Pulmonary edema, dyspnea (shortness of breath), labored breathing, respiratory depression, or respiratory arrest may also occur. Emergency Life-Support Procedures: Acute exposure to physostigmine may require decontamination and life support for the victims. Emergency personnel should wear protective clothing appropriate to the type and degree of contamination. Air-purifying or supplied-air respiratory equipment should also be worn, as necessary. Rescue vehicles should carry supplies such as plastic sheeting and disposable plastic bags to assist in preventing spread of contamination. Inhalation Exposure: 1. Move victims to fresh air. Emergency personnel should avoid self-exposure to physostigmine. 2. Evaluate vital signs including pulse and respiratory rate, and note any trauma. If no pulse is detected, provide CPR. If not breathing, provide artificial respiration. If breathing is labored, administer oxygen or other respiratory support. 3. Obtain authorization and/or further instructions from the local hospital for administration of an antidote or performance of other invasive procedures. 4. Rush to a health care facility. Dermal/Eye Exposure: 1. Remove victims from exposure. Emergency personnel should avoid self-exposure to physostigmine. 2. Evaluate vital signs including pulse and respiratory rate, and note any trauma. If no pulse is detected, provide CPR. If not breathing, provide artificial respiration. If breathing is labored, administer oxygen or other respiratory support. 3. Remove and isolate contaminated clothing as soon as possible. 4. If eye exposure has occurred, eyes must be flushed with lukewarm water for at least 15 minutes. 5. Wash exposed skin areas thoroughly with water. 6. Obtain authorization and/or further instructions from the local hospital for administration of an antidote or performance of other invasive procedures. 7. Rush to a health care facility. Ingestion Exposure: 1. Evaluate vital signs including pulse and respiratory rate, and note any trauma. If no pulse is detected, provide CPR. If not breathing, provide artificial respiration. If breathing is labored, administer oxygen or other respiratory support. 2. Obtain authorization and/or further instructions from the local hospital for administration of an antidote or performance of other invasive procedures. 3. Vomiting may be induced with syrup of Ipecac. If elapsed time since ingestion of physostigmine is unknown or suspected to be greater than 30 minutes, do not induce vomiting and proceed to Step 4. Ipecac should not be administered to children under 6 months of age. Warning: Ingestion of physostigmine may result in sudden onset of seizures or loss of consciousness. Syrup of Ipecac should be administered only if victims are alert, have an active gag reflex, and show no signs of impending seizure or coma. If ANY uncertainty exists, proceed to Step 4. The following dosages of Ipecac are recommended: children up to 1 year old, 10 mL (1/3 oz); children 1 to 12 years old, 15 mL (1/2 oz); adults, 30 mL (1 oz). Ambulate (walk) the victims and give large quantities of water. If vomiting has not occurred after 15 minutes, Ipecac may be readministered. Continue to ambulate and give water to the victims. If vomiting has not occurred within 15 minutes after second administration of Ipecac, administer activated charcoal. 4. Activated charcoal may be administered if victims are conscious and alert. Use 15 to 30 g (1/2 to 1 oz) for children, 50 to 100 g (1-3/4 to 3-1/2 oz) for adults, with 125 to 250 mL (1/2 to 1 cup) of water. 5. Promote excretion by administering a saline cathartic or sorbitol to conscious and alert victims. Children require 15 to 30 g (1/2 to 1 oz) of cathartic; 50 to 100 g (1-3/4 to 3 1/2 oz) is recommended for adults. 6. Rush to a health care facility. (EPA, 1998)

Recommended treatment for physostigmine overdose includes: Maintenance of open airway (possible suction of bronchial secretions); use of assisted respiration. Monitoring of cardiac function. Intravenous administration of atropine sulfate in doses of 2 to 4 mg; may be repeated every 3 to 10 minutes, if necessary to control muscarinic effects. Intravenous administration of pralidoxime chloride at a rate of 50 to 100 mg per minute, to counteract ganglionic and skeletal muscle effects. Treatment of convulsions or shock as appropriate.

GI SYMPTOMS OCCUR EARLIEST AFTER INGESTION, & INCL ANOREXIA, NAUSEA & VOMITING, ABDOMINAL CRAMPS, & DIARRHEA. WITH PERCUTANEOUS ABSORPTION OF LIQ, LOCALIZED SWEATING & MUSCULAR FASCICULATION IN IMMEDIATE VICINITY ARE GENERALLY EARLIEST MANIFESTATIONS. /ANTI-CHOLINESTERASE AGENTS/|EFFECTS ON CNS INCL CONFUSION, ATAXIA, SLURRED SPEECH, LOSS OF REFLEXES, CHEYNE-STOKES RESPIRATION, GENERALIZED CONVULSIONS, COMA, & CENTRAL RESP PARALYSIS. ... TIME OF DEATH AFTER SINGLE ACUTE EXPOSURE ... 5 MIN TO NEARLY 24 HR, DEPENDING UPON DOSE, ROUTE ... CAUSE OF DEATH ... RESP FAILURE ... /&/ SECONDARY CARDIOVASCULAR COMPONENT. /ANTI-CHOLINESTERASE AGENTS/|AFTER LOCAL EXPOSURE TO VAPORS OR ... INHALATION, OCULAR PAIN & RESP EFFECTS GENERALLY APPEAR FIRST. OCULAR ... INCL MARKED MIOSIS, OCCULAR PAIN, CONJUNCTIVAL CONGESTION, DIMINISHED VISION, CILIARY SPASM, & BROW ACHE. IN ADDITION TO RHINORRHEA AND HYPEREMIA OF THE UPPER RESP TRACT, RESP EFFECTS CONSIST OF "TIGHTNESS" IN CHEST & WHEEZING RESP, CAUSED BY ... BRONCHOCONSTRICTION & INCR BRONCHIAL SECRETION. /ANTI-CHOLINESTERASE AGENTS/|NICOTINIC ACTIONS @ NEUROMUSCULAR JUNCTIONS OF SKELETAL MUSCLE ... FATIGABILITY & GENERALIZED WEAKNESS, INVOLUNTARY TWITCHINGS ... SEVERE WEAKNESS & PARALYSIS; A CENTRAL COMPONENT OF ACTION CONTRIBUTES TO SOME OF THESE EFFECTS. THE MOST SERIOUS CONSEQUENCE ... IS PARALYSIS OF RESPIRATORY MUSCLES. /ANTI -CHOLINESTERASE AGENTS/|For more Human Toxicity Excerpts (Complete) data for PHYSOSTIGMINE (18 total), please visit the HSDB record page.

Eserine

PHYSOSTIGMINE IS GENERALLY USED AS SALICYLATE OR SULFATE SALT; SALICYLATE HAS ADVANTAGE OF BEING LESS DELIQUESCENT ... ADDITION OF FEW GRAINS BORIC ACID TO SOLN OF SALT ... INHIBIT FORMATION OF RED DECOMP PRODUCT ... .|PHYSOSTIGMINE, USP (ESERINE), PHYSOSTIGMINE SALICYLATE, USP, & PHYSOSTIGMINE SULFATE, USP ARE AVAILABLE AS CRYSTALLINE POWDERS FOR COMPOUNDING ORAL & PARENTERAL PREPN IN SUITABLE DOSAGE FORMS.|PHYSOSTIGMINE SALICYLATE (ANTILIRIUM) IS AVAILABLE AS A SOLUTION (1 MG/ML) FOR INJECTION. PHYSOSTIGMINE SULFATE OPHTHALMIC OINTMENT (0.25%) & PHYSOSTIGMINE SALICYLATE OPHTHALMIC SOLUTION (0.25% & 0.5%), ARE ALSO AVAILABLE.|Ophthalmic solution (as the salicylate), 0.25% and 0.5%. Ophthalmic ointment (as the sulfate), 0.25%. Ampules and syringes (as the salicylate), 1 mg/ml.|For more Formulations/Preparations (Complete) data for PHYSOSTIGMINE (8 total), please visit the HSDB record page.

Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-methylcarbamate), (3aS,8aR)-: ACTIVE|THE VIABILITY OF THE CONDITIONED FLAVOR AVERSION TEST AS A BEHAVIORAL INDEX OF THE TOXICITY OF PHYSOSTIGMINE WAS EVALUATED IN A SERIES OF THREE EXPERIMENTS. IT WAS CONCLUDED THAT THE FLAVOR AVERSION TEST IS A SIMPLE AND SENSITIVE BEHAVIORAL MEASURE OF TOXICITY.|Available as the salicylate and sulfate.

Determination of physostigmine in drug ointments by using chromatographic/ spectrophotometer at the range of 265-400 nm.|A reversed-phase, ion-pairing HPLC method was developed for the analyses of physostigmine containing pharmaceuticals in the presence of its decomposition products, eseroline and rubreserine, and preservatives, methyl- and propylparabens.

QUANTITATIVE ASSAY OF PHYSOSTIGMINE IN HUMAN BLOOD WAS CONDUCTED. CHOLINESTERASE ACTIVITY MEASURED. THE TIME REQUIRED FOR ENZYME REACTIVATION IS RELATED TO PHYSOSTIGMINE CONCN.|A method for physostigmine determination in blood plasma with a detection limit of 50 pg/ml was developed. The drug was extracted by hexane in a 1 step procedure after pH buffering with sodium bicarbonate. Samples were analyzed on a 25 cm X 4.6 mm I.D. silica column (5 um particle size) using a mixture of acetonitrile, methanol, and 0.08 M ammonium nitrate buffer pH 8.90 (50:40:10) as a mobile phase. Since the drug is quite unstable in blood plasma, pyridostigmine bromide was added to the samples to limit the decomposition. Physostigmine was used as an internal standard. The drug was electrochemically detected by oxidizing potential (+0.75 V).|A HPLC post column fluorescent ion pair extraction system was developed for the analysis of quaternary ammonium and amine drugs in serum. Physostigmine and its metabolite eseroline were used as model cations. Detection limits based on a signal-to-noise ratio of 2, were 2 and 5 ng/ml, respectively. Precision of the method was found to be in the 1.5-3% range and percentage error in the 1.5-7% range for both cmpd.|Physostigmine was determined in plasma and CSF by HPLC with electrochemical detection, with use of a normal phase column and methanolic sodium acetate buffer, pH 4.6. The detection limit of the method was 0.5 ug/l for a 2 ml sample of plasma or 0.5 ml of CSF. Analytical recovery of physostigmine in the range 0.5-40 ug/l was 60% (standard deviation 5%) for plasma and 78% (standard deviation 8%) for CSF.|TISSUE SAMPLE, FLUOROMETRIC ANALYSIS, EXCITATION 290 NM/EMISSION 350 NM.

Human Drugs -> EU pediatric investigation plans|Pharmaceuticals